StockData
Nuvation Bio Inc. logo

Nuvation Bio Inc. (NUVB) stock

NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.90+0.06 (+1.56%)

Close on Nov 17, 2026Market cap $1.37BP/E –Yield –

Nuvation Bio r&d expenses

Research and development expenses are spending on new products and technology.

Nuvation Bio's R&D Expenses for the twelve months ending Jun 30, 2026 was $128.85M, up 18.2% year over year. For fiscal 2025 it was $115.11M, up 16.1% from the year before. The highest annual figure on record is $115.11M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$115.11M+16.1%
FY2024Dec 31, 2024$99.12M+39.0%
FY2023Dec 31, 2023$71.29M-18.8%
FY2022Dec 31, 2022$87.82M+27.2%
FY2021Dec 31, 2021$69.04M+111.8%
FY2020Dec 31, 2020$32.60M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$30.66M+12.1%
Q1 FY2026Mar 31, 2026$35.05M+42.5%
Q4 FY2025Dec 31, 2025$34.30M+17.1%
Q3 FY2025Sep 30, 2025$28.85M+4.0%
Q2 FY2025Jun 30, 2025$27.36M-6.4%
Q1 FY2025Mar 31, 2025$24.60M+91.6%
Q4 FY2024Dec 31, 2024$29.30M+90.9%
Q3 FY2024Sep 30, 2024$27.73M+49.4%
Q2 FY2024Jun 30, 2024$29.25M+57.3%
Q1 FY2024Mar 31, 2024$12.84M-31.6%
Q4 FY2023Dec 31, 2023$15.35M-9.0%
Q3 FY2023Sep 30, 2023$18.56M-12.8%
Q2 FY2023Jun 30, 2023$18.59M-35.7%
Q1 FY2023Mar 31, 2023$18.79M-9.4%
Q4 FY2022Dec 31, 2022$16.87M-23.3%
Q3 FY2022Sep 30, 2022$21.29M+24.4%
Q2 FY2022Jun 30, 2022$28.92M+106.1%
Q1 FY2022Mar 31, 2022$20.73M+30.5%
Q4 FY2021Dec 31, 2021$22.00M+135.7%
Q3 FY2021Sep 30, 2021$17.12M+98.5%
Q2 FY2021Jun 30, 2021$14.03M+91.1%
Q1 FY2021Mar 31, 2021$15.88M+117.7%
Q4 FY2020Dec 31, 2020$9.34M–
Q3 FY2020Sep 30, 2020$8.63M–
Q2 FY2020Jun 30, 2020$7.35M–
Q1 FY2020Mar 31, 2020$7.30M–

More Nuvation Bio figures

See a number that looks wrong?